Lilly, MDLinx launch oncology journal app

Share this article:

Eli Lilly is going bigger in the cancer space, and is drawing attention to its efforts with a one-year sponsorship of an MDLinx journal aggregator app called MDLinx Oncology Articles, which the company presented at last month's American Society of Clinical Oncology conference in Chicago.

The app pools information from more than 150 oncology journals which are screened by MDLinx staff. Carla Cox, director of communications for Lilly Oncology told MM&M that the drug maker has no say in what MDLinx's editorial staff selects and that "there will not be any promotion of any Lilly product."

Cox said the drug maker knows “we need to go above and beyond. That we also now need to work very closely with our customers and physicians to make sure they have access to the right [kind] of information they need,” and the goal was to “put it right in the palm of their hand.”

Cox says Lilly had been thinking about an app for some time – the company already has clinical trial and pipeline apps – but decided to look outside for a research tool instead of simply replicating what is already on the market. Like other journal aggregators, the MDLinx app allows users to share abstracts and define the type of content they want, drilling down to include criteria such as tumor types. The daily content includes editorial summaries and access to third-party reviews and is currently scaled for phones as opposed to tablets.

Cox says Lilly would look into additional platforms, but lead with phones based on preference research. She says that while ROI for such things “fall into that gray space,” the company will use feedback to gauge the app's impact and to figure out if it wants to call in its right to renew sponsorship once the year-long contract is up.

In addition to ASCO, Lilly is promoting the apps at the European Society of Medical Oncology and the World Conference on Lung Cancer. The Indiana company is also using sales rep leave-behinds to promote the app, and says promotion will continue to increase as global affiliates green-light the tool and begin talking it up through local channels.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...